How AI Is Accelerating Drug Discovery with Smbat Rafayelyan
Amid a rapidly changing biotech landscape, innovation and data are redefining how we discover and develop new medicines.
In this episode, I sit down with Smbat Rafayelyan, founder and CEO of Bioneex, a platform that connects early-stage biotech innovators with investors and pharma companies through AI-driven insights. Smbat shares his journey from big pharma to entrepreneurship and how his team is reshaping the landscape of drug discovery.
We explore how personalized large language models are being applied in biotech, the growing role of AI in identifying and evaluating assets, and what’s fueling the surge of innovation coming from China’s biotech sector. Throughout the conversation, Smbat offers thoughtful insights on how human expertise and technology intersect to accelerate medical innovation.
If you’ve ever wondered how AI is making sense of scientific data chaos, this episode is a must-listen.
Specifically, this episode highlights the following themes:
- How personalized AI models improve drug discovery and evaluation
- The role of data integration in connecting biotech, pharma, and investors
- Global opportunities, including China’s emerging biotech ecosystem
Links from this episode:
- Get to know more about Steven Swan: https://www.linkedin.com/in/swangroup
- Get to know more about Smbat Rafayelyan: https://www.linkedin.com/in/dr-smbat-rafayelyan/?originalSubdomain=de
- Learn more about Bioneex: https://bioneex.com
==== Time Stamps ====
00:00 – Introduction
02:50 – The gap that led to creating Bioneex
08:26 – Using AI and large language models in biotech
14:58 – Why super-personalized LLMs outperform general models
18:49 – The growing influence of Chinese biotech innovation
22:40 – Who uses Bioneex and how the platform works
26:44 – A case study: Stanford biotech success story
30:38 – Partnering with AI-driven drug prediction firms
